Satellos Bioscience (MSCL) Corporate presentation summary

Mission and scientific foundation

• Aims to transform the lives of those with Duchenne muscular dystrophy (DMD) and other muscle diseases by restoring natural muscle regeneration.

• Founded in 2018, operates at the clinical stage, and is listed on TSX and NASDAQ.

• Scientific approach based on Dr. Michael Rudnicki’s discovery that DMD is primarily a disease of failed muscle regeneration.

• SAT-3247 is a first-in-class, oral, once-daily tablet designed to regenerate muscle and potentially modify disease progression.

Disease background and unmet need

• DMD affects 1 in 5,000 male births globally, with about 12,000 affected in the U.S.

• No approved therapies currently exist that regenerate muscle; existing treatments have significant limitations.

• DMD progression involves early muscle function, followed by progressive loss and premature death, often from cardiorespiratory failure.

Mechanism of action and preclinical evidence

• DMD muscle stem cells fail to produce enough progenitor cells for repair, leading to muscle degeneration.

• SAT-3247 inhibits AAK1 to restore muscle stem cell polarity and enable regeneration, compensating for the absence of dystrophin.

• Preclinical canine studies showed up to 4x strength gain and enhanced muscle regeneration after SAT-3247 treatment.